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possibility of “personalized med-
icine.” Despite such progress, the 
way in which a physician uses 
biomarkers recapitulates an endur-
ing practice of medicine: measure 
the patient, think about the result, 
and make a decision.
With these advancements, U.S. 
researchers and companies have 
also claimed patents on their bio-
marker discoveries. These patents 
have generated controversy over 
whether they hinder the practice 
of medicine and research by cover-
ing not just the actual test but 
also the use of the biomarker 
generally in making diagnoses 
and discovering new applications. 
This year, a lawsuit over one such 
patent reached the Supreme Court 
in Mayo Collaborative Services v. Pro-
metheus Laboratories,1 the outcome 
of which may substantially alter 
the role of patents in biomarker 
discovery and clinical application.
The controversy originated in 
the mid-1990s, when researchers 
discovered that blood levels of 
azathioprine metabolites could 
guide the treatment of inflam-
matory bowel disease. Their pat-
ents on their discoveries covered, 
among other similar claims, ad-
ministering azathioprine and mea-
suring the level of a metabolite of 
the drug (see diagram): a level be-
low 230 pmol per 8×108 red cells 
suggested the need to increase the 
dose, while a level above 400 pmol 
per 8×108 red cells suggested the 
need to reduce it. The researchers 
licensed their patents, including 
the one covering this dose-adjust-
ment method, exclusively to Pro-
metheus Laboratories to use in 
commercializing a diagnostic test.
Mayo Medical Laboratories ini-
tially sent out its specimens to Pro-
metheus for analysis and recom-
mendations that used the patented 
correlations. After some time, 
however, Mayo’s researchers cre-
ated what they believed was a 
more accurate assay that employed 
slightly different cut points for 
adjusting azathioprine doses. Mayo 
adopted this new assay and 
priced it 25% below the price of 
Prometheus’s test.2 Prometheus 
sued for patent infringement.
U.S. law permits patents for 
processes or methods that also 
meet the other requirements in 
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the patent statute, including be-
ing novel and “nonobvious,” or en-
tailing a sufficient advance over 
existing knowledge. Traditionally, 
the primary rule covering whether 
a process is patentable was that 
the process could not be a law of 
nature, such as a mathematical 
formula or scientific algorithm. 
However, it was permissible to 
use a law of nature in an inven-
tive process; in one famous case, 
for instance, a patent involved the 
use of the Arrhenius equation of 
thermodynamics as part of an 
inventive process for making syn-
thetic rubber. The Court of Ap-
peals for the Federal Circuit, the 
highest patent court below the 
Supreme Court, had implemented 
this rule by requiring that a pro-
cess produce a “useful, concrete 
and tangible result” in order to be 
patentable.
The nebulous boundaries of a 
law of nature, however, led to a 
proliferation of patents in the 
health care field, covering various 
basic-science discoveries and es-
sential steps in medical decision 
making. Dissatisfaction over these 
broad patents first reached the 
Supreme Court in 2006 in a con-
troversy over a patented process 
covering the association between 
an elevated blood homocysteine 
level and the diagnosis of vita-
min B12 or folate deficiencies.3 
But the Court ultimately decided 
not to hear the case, leaving the 
patent intact over a scathing dis-
sent from Justice Stephen Breyer, 
who considered this process to 
be “a simple natural correlation.”
After that opinion was issued, 
the Federal Circuit announced a 
new standard for patenting a pro-
cess: to be distinguished from a 
law of nature, the process must 
be related to a machine or cause 
a transformation of matter. How-
ever, in a 2010 case that unani-
mously overturned a patent for a 
business method for hedging in-
vestment risk, the Supreme Court 
also narrowly rejected this test as 
the sole determinant of patent-
ability, because such a limitation 
might improperly exclude future 
technology from patenting.4
The Prometheus Laboratories 
dispute reached the Court soon 
after that ruling was issued. Pro-
metheus argued that its drug–
metabolite correlations were pat-
entable because the process of 
identifying the metabolite level, 
which led to treatment adjust-
ments, would not occur “but for 
the handiwork of man” in creat-
ing azathioprine. The U.S. Solici-
tor General sided with Prometheus 
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in principle but argued that these 
specific patents might not meet 
the tests of novelty or nonobvi-
ousness.
But Justice Breyer, this time 
writing for a unanimous court, 
found the claimed intellectual 
property to be an unpatentable 
law of nature because it restated a 
basic scientific discovery and sim-
ply instructed physicians “to gath-
er data from which they may draw 
an inference.” The court held 
that “if a law of nature is not 
patentable, then neither is a pro-
cess reciting a law of nature,” 
and Prometheus’s patent “amounts 
to nothing significantly more than 
an instruction to doctors to apply 
the applicable laws when treating 
their patients.”
With this decision, the Supreme 
Court has taken a bold step, pro-
scribing patents from covering 
correlations used in making bio-
marker-based diagnoses when 
those patents simply describe 
“steps that must be taken in or-
der to apply” the natural law in 
question. In addition, bundling the 
diagnosis with the step of admin-
istering a man-made drug does 
not make a biomarker discovery 
a patentable invention. A patent-
able process now needs to involve 
an inventive and novel application 
of a law of nature beyond “well-
understood, routine, conventional 
activity, previously engaged in by 
those in the field.”
The Court’s argument would 
have applied to the earlier homo-
cysteine case and would also ap-
ply to a range of other diagnostic 
patents. For example, after Mayo 
Collaborative Services, the Federal Cir-
cuit must also revisit a lawsuit 
challenging patents held by Myriad 
Genetics that cover the BRCA DNA 
sequences and the process of us-
ing the genes to identify patients 
who are at risk for breast cancer. 
In light of the decision, the diag-
nostic patents at issue are not like-
ly to survive. However, it is less 
certain whether the more robust 
definition of a law of nature laid 
out by the Court will extend to 
other fields and invalidate the 
patents on the essential DNA se-
quences as well.
Also uncertain is the decision’s 
effect on patents covering the use 
of a diagnostic method as one 
step in a larger process of treating 
patients, such as so-called thera-
nostic processes that link bio-
markers with safe and effective 
drug use. Increasingly, new treat-
ments, especially ones for cancer, 
are being codeveloped with bio-
marker assays that guide their use. 
The U.S. Patent Office will now 
face the task of distinguishing 
the development and characteriza-
tion of these biomarkers from 
other “processes” that simply com-
bine a test for a drug metabolite 
with a dosing algorithm.
Excluding some medical dis-
coveries from the possibility of 
patenting has led some observers 
to worry about the implications 
for private investment. Industry 
trade groups have argued that 
process patents are essential for 
recouping the costs of biomarker 
innovation. Justice Breyer suggest-
ed that Congress could consider 
whether innovation in diagnostic 
methods needed special market-
exclusivity protection. In our view, 
a better option would be to in-
crease public funding for bio-
marker discovery and develop-
ment. The Foundation for the 
National Institutes of Health, an 
independent nonprofit organiza-
tion, has spawned more than 
100 projects in this area, includ-
ing the Biomarkers Consortium, a 
public–private partnership invest-
ing in the discovery of biomarkers 
for Alzheimer’s disease and other 
conditions. In genomics, less sci-
entific research and product de-
velopment have been done on gene 
sequences covered by intellectual 
property rights than on compa-
rable sequences promulgated 
through an open-source model.5 
If the Supreme Court’s move to 
free the fundamental processes of 
medical diagnosis from private 
ownership supports greater inter-
est in such consortia, it could ulti-
mately enhance the public health.
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